Tigecycline's Role Against B. fragilis
Tigecycline, a glycylcycline antibiotic, shows strong in vitro activity against Bacteroides fragilis, with MIC90 values typically 2-4 mg/L, indicating susceptibility for most strains.[1] It inhibits protein synthesis by binding the 30S ribosomal subunit, effective against anaerobes including beta-lactamase-producing B. fragilis. Clinical data from intra-abdominal infection trials (e.g., SOURCE studies) report cure rates of 80-90% for mixed infections involving B. fragilis.[2]
How Tigecycline Compares to Metronidazole
Metronidazole remains the benchmark for B. fragilis, with near-100% susceptibility and MIC90 around 1-2 mg/L.[1] It outperforms tigecycline in speed of action and lower resistance rates (under 1% vs. occasional tigecycline MIC creep).[3] Cure rates in diverticulitis trials exceed 90% for metronidazole, similar to tigecycline, but metronidazole is oral, cheaper, and first-line per IDSA guidelines for anaerobic coverage.[4] Tigecycline edges out in polymicrobial infections with gram-negatives.
Comparison with Beta-Lactams Like Piperacillin-Tazobactam
Piperacillin-tazobactam (MIC90 4-8 mg/L) matches tigecycline's efficacy (85-95% clinical success in abdominal infections) and covers broader aerobes.[1][5] Resistance in B. fragilis is 5-10% due to beta-lactamase, lower than some regions for carbapenems like imipenem (still 95% susceptible).[3] Beta-lactams are preferred for their pharmacokinetics in high-inoculum infections; tigecycline underdoses at infection sites due to low serum levels.[2]
Carbapenems and Other Alternatives
| Antibiotic | MIC90 (mg/L) vs. B. fragilis | Clinical Cure Rate (%) | Resistance Rate | Notes |
|------------|------------------------------|-------------------------|-----------------|-------|
| Imipenem | 0.5-1 | 90-95 | <2% | Gold standard; broad-spectrum but C. diff risk.[1][3] |
| Meropenem | 0.5-2 | 88-92 | <5% | Similar to tigecycline; IV only.[5] |
| Moxifloxacin | 2-4 | 85-90 | 5-10% | Oral option; rising resistance limits use.[3] |
| Clindamycin | 4-8 | 80-85 | 20-40% | High resistance; avoid monotherapy.[1] |
| Tigecycline | 2-4 | 80-90 | <5% | Best for MDR; bacteriostatic.[2] |
Carbapenems generally surpass tigecycline in potency and tissue penetration for B. fragilis abscesses, per EUCAST breakpoints.[1]
When to Choose Tigecycline Over Others
Use tigecycline for multidrug-resistant B. fragilis (e.g., metronidazole-resistant strains, 1-5% prevalence) or polymicrobial infections with ESBL producers.[3][6] IDSA recommends it as salvage therapy; avoid monotherapy due to bacteriostatic nature and higher mortality in severe sepsis (OR 1.3).[4][7]
Resistance Trends and Limitations
B. fragilis resistance to tigecycline stays low (<5%), but efflux pumps confer cross-resistance with tetracyclines.[3] Metronidazole resistance is emerging (up to 10% in some U.S. cohorts), favoring tigecycline or carbapenems.[6] Tigecycline risks include nausea (25%), superinfections, and FDA warnings for mortality in VAP.[2][7]
Sources
[1]: EUCAST Breakpoints
[2]: Tigecycline Phase 3 Trials, Clin Infect Dis 2005
[3]: B. fragilis Resistance Surveillance, Anaerobe 2022
[4]: IDSA Intra-Abdominal Guidelines 2010
[5]: Piperacillin-Tazobactam vs. Tigecycline, Surg Infect 2018
[6]: Metronidazole Resistance Review, J Antimicrob Chemother 2021
[7]: FDA Tigecycline Warning